Navidea Biopharmaceuticals Inc EV/EBITDA
What is the EV/EBITDA of Navidea Biopharmaceuticals Inc?
The EV/EBITDA of Navidea Biopharmaceuticals Inc is N/A
What is the definition of EV/EBITDA?
EV/EBITDA is enterprise value divided by earnings before interest, tax, depreciation, and amortization. It is a measure of how expensive a stock is and is more frequently valid for comparisons across companies than the price to earnings ratio. It measures the price (in the form of enterprise value) an investor pays for the benefit of the company’s cash flow (in the form of EBITDA).
= enterprise value / EBITDA
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV/EBITDA of companies in the Health Care sector on NYSEMKT compared to Navidea Biopharmaceuticals Inc
What does Navidea Biopharmaceuticals Inc do?
navidea biopharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. it operates through two segments, diagnostic substances and therapeutic development programs. the company develops manocept platform to target the cd206 mannose receptor expressed on activated macrophages. its cd206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (pet), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. further, the company offers nav4694, a fluorine-18 labeled pet imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of alzheimer's disease and mild cognitive impairment. in addition, it is de
Companies with ev/ebitda similar to Navidea Biopharmaceuticals Inc
- Amigo PLC has EV/EBITDA of N/A
- Surgalign has EV/EBITDA of N/A
- Catasys has EV/EBITDA of N/A
- Goldhills has EV/EBITDA of N/A
- Just Kitchen has EV/EBITDA of N/A
- Alternate Health has EV/EBITDA of N/A
- Navidea Biopharmaceuticals Inc has EV/EBITDA of N/A
- Tombill Mines has EV/EBITDA of N/A
- Grand Talents has EV/EBITDA of N/A
- CV Sciences has EV/EBITDA of N/A
- Angold Resources has EV/EBITDA of N/A
- Adamis Pharmaceuticals Corp has EV/EBITDA of N/A
- Ovid Therapeutics Inc has EV/EBITDA of N/A